We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-4.77%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.61B
AUM Growth
-$151M
Cap. Flow
-$42.4M
Cap. Flow %
-2.62%
Top 10 Hldgs %
46.28%
Holding
103
New
28
Increased
9
Reduced
25
Closed
20

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$24.3M
2
IJH icon
iShares Core S&P Mid-Cap ETF
IJH
+$22.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.6M
4
BHVN icon
Biohaven
BHVN
+$20.2M
5
RSP icon
Invesco S&P 500 Equal Weight ETF
RSP
+$19.5M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$92.8M
2
MRK icon
Merck
MRK
+$61.6M
3
ACHC icon
Acadia Healthcare
ACHC
+$43.5M
4
ELV icon
Elevance Health
ELV
+$29.3M
5
AMGN icon
Amgen
AMGN
+$29.1M

Sector Composition

Rank Sector Weight
1 Healthcare 75.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LBPH
101
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
– –
-113,711
Closed -$3.79M
1 2 3 4
5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

PFM Health Sciences's Q4 2024 Portfolio in Review

As of Q4 2024, PFM Health Sciences held 103 positions worth $1.61B, down 8.6% from $1.76B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

PFM Health Sciences's Q4 2024 filing shows 28 new, 9 increased, 25 reduced and 20 closed positions. Its largest new stake was DexCom: 328,763 shares worth $25.6M. The largest sale was Cytokinetics, an estimated $92.8M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 96% a quarter earlier.

  • PFM Health Sciences's largest Q4 2024 buy was DexCom: 328,763 shares worth $25.6M.
  • PFM Health Sciences added most to Edwards Lifesciences in Q4 2024, an estimated $14.2M increase.
  • PFM Health Sciences's biggest Q4 2024 reduction was Intuitive Surgical, cutting an estimated $23M.
  • PFM Health Sciences fully exited Cytokinetics in Q4 2024, selling an estimated $92.8M.
  • PFM Health Sciences's ten largest holdings make up 46% of its $1.61B portfolio in Q4 2024.
  • PFM Health Sciences opened 28 new positions and closed 20 in Q4 2024.
  • PFM Health Sciences's portfolio value fell 8.6% quarter-over-quarter to $1.61B.

Based on PFM Health Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.